Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06260059 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06260059 · ClinicalTrials.gov record · last posted 2025-10-06

Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease

Name: Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease — clinical trial record (NCT06260059)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: EmpaCHD

StatusRecruiting

PhasePhase 4

SponsorAnita Saraf

Started2024-09-17

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).

Amendment record 4 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 4 times since 2024-02-13; most recent amendment 2025-10-02. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-08-01

Status change Not Yet Recruiting→Recruitingv1

Trial Details

NCT Number	NCT06260059
Lead Sponsor	Anita Saraf Collaborators: The Pittsburgh Foundation
Conditions	Adult Congenital Heart Disease, Heart Failure
Enrollment	40 participants
Start Date	2024-09-17
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-06-01 (estimated)
Updated on ClinicalTrials.gov	2025-10-06